ROY, Sudeep, Akhil KUMAR, Mohd Hassan BAIG, Michal MASAŘÍK a Ivo PROVAZNÍK. Virtual screening, ADMET profiling, molecular docking and dynamics approaches to search for potent selective natural molecules based inhibitors against metallothionein-III to study Alzheimer's disease. Methods. San Diego: Academic Press Inc. Elsevier Science, 2015, roč. 83, "15 July 2015", s. 105-110. ISSN 1046-2023. Dostupné z: https://dx.doi.org/10.1016/j.ymeth.2015.04.021.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Virtual screening, ADMET profiling, molecular docking and dynamics approaches to search for potent selective natural molecules based inhibitors against metallothionein-III to study Alzheimer's disease
Autoři ROY, Sudeep (203 Česká republika), Akhil KUMAR (356 Indie), Mohd Hassan BAIG (410 Korejská republika), Michal MASAŘÍK (203 Česká republika, garant, domácí) a Ivo PROVAZNÍK (203 Česká republika, domácí).
Vydání Methods, San Diego, Academic Press Inc. Elsevier Science, 2015, 1046-2023.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 10600 1.6 Biological sciences
Stát vydavatele Spojené státy
Utajení není předmětem státního či obchodního tajemství
Impakt faktor Impact factor: 3.503
Kód RIV RIV/00216224:14110/15:00083935
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1016/j.ymeth.2015.04.021
UT WoS 000358755100013
Klíčová slova anglicky Alzheimer's disease; Metallothionein-III; Virtual screening; ADMET; Molecular dynamics
Štítky EL OK
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Soňa Böhmová, učo 232884. Změněno: 22. 9. 2015 15:28.
Anotace
Motivation: Metallothionein-III (MT-III) displays neuro-inhibitory activity and is involved in the repair of neuronal damage. An altered expression level of MT-III suggests that it could be a mitigating factor in Alzheimer's disease (AD) neuronal dysfunction. Currently there are limited marketed drugs available against MT-III. The inhibitors are mostly pseudo-peptide based with limited ADMET. In our present study, available database InterBioScreen (natural compounds) was screened out for MT-III. Pharmacodynamics and pharmacokinetic studies were performed. Molecular docking and simulations of top hit molecules were performed to study complex stability. Results: Study reveals potent selective molecules that interact and form hydrogen bonds with amino acids Ser-6 and Lys-22 are common to established melatonin inhibitors for MT-III. These include DMHMIO, MCA B and s27533 derivatives. The ADMET profiling was better with comparable interaction energy values. It includes properties like blood brain barrier, hepatotoxicity, druggability, mutagenicity and carcinogenicity. Molecular dynamics studies were performed to validate our findings.
VytisknoutZobrazeno: 5. 10. 2024 01:45